Mirae Asset Global Investments Co. Ltd. Increases Position in LivaNova PLC (NASDAQ:LIVN)

Mirae Asset Global Investments Co. Ltd. boosted its holdings in LivaNova PLC (NASDAQ:LIVN) by 6.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,981 shares of the company’s stock after purchasing an additional 1,779 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in LivaNova were worth $1,499,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BlackRock Inc. increased its position in shares of LivaNova by 6.4% during the first quarter. BlackRock Inc. now owns 7,271,165 shares of the company’s stock valued at $316,877,000 after acquiring an additional 436,552 shares in the last quarter. Primecap Management Co. CA increased its position in shares of LivaNova by 7.3% during the third quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock valued at $305,930,000 after acquiring an additional 395,940 shares in the last quarter. State Street Corp increased its position in shares of LivaNova by 6.8% during the third quarter. State Street Corp now owns 2,556,625 shares of the company’s stock valued at $129,800,000 after acquiring an additional 162,744 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of LivaNova by 143.0% during the second quarter. Alliancebernstein L.P. now owns 2,225,363 shares of the company’s stock valued at $114,450,000 after acquiring an additional 1,309,486 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of LivaNova by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock valued at $93,612,000 after acquiring an additional 100,133 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Barclays raised their target price on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of LivaNova in a report on Wednesday, March 20th. Mizuho restated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Wednesday, March 27th. StockNews.com cut shares of LivaNova from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. Finally, Robert W. Baird raised their target price on shares of LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, February 22nd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $64.40.

LivaNova Trading Down 0.8 %

Shares of LivaNova stock opened at $52.33 on Monday. The company’s fifty day simple moving average is $53.58 and its 200-day simple moving average is $50.52. The stock has a market capitalization of $2.82 billion, a PE ratio of 163.54 and a beta of 0.89. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $59.86. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.10. The business had revenue of $310.10 million for the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company’s revenue was up 12.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.81 EPS. As a group, equities analysts anticipate that LivaNova PLC will post 3.01 earnings per share for the current year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.